These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16990079)

  • 21. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Ozsener S; Sendag F; Koc T; Terek MC; Oztekin K; Bilgin O
    J Obstet Gynaecol Res; 2001 Dec; 27(6):353-8. PubMed ID: 11794823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
    Marschang P; Sandhofer A; Ritsch A; Fiŝer I; Kvas E; Patsch JR
    J Intern Med; 2006 Aug; 260(2):151-9. PubMed ID: 16882279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
    Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
    J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
    Pfeffer MA; Sacks FM; Moyé LA; East C; Goldman S; Nash DT; Rouleau JR; Rouleau JL; Sussex BA; Theroux P; Vanden Belt RJ; Braunwald E
    J Am Coll Cardiol; 1999 Jan; 33(1):125-30. PubMed ID: 9935018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
    Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing angiographic progression of coronary atherosclerosis with pravastatin.
    Daida H; Ouchi Y; Saito Y; Yamada N; Nishide T; Mokuno H; Kurata T; Sato H; Eto M; Ako JY; Tango T; Yamaguchi H;
    J Atheroscler Thromb; 2003; 10(1):25-31. PubMed ID: 12621161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
    Kawaguchi A; Mitsudo K; Nobuyoshi M; Minamino R; Hayasaki K; Nakashima M; Yamamoto A;
    J Cardiovasc Risk; 2002 Feb; 9(1):7-16. PubMed ID: 11984212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
    Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins improve visual field alterations related to hypercholesterolemia.
    Alcalá A; Jansen S; Téllez T; Gómez-Huelgas R; Pérez O; Egido J; Farkouh ME
    Atherosclerosis; 2010 Apr; 209(2):510-4. PubMed ID: 19892351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
    Koh KK; Quon MJ; Sakuma I; Han SH; Choi H; Lee K; Shin EK
    Int J Cardiol; 2013 Jun; 166(2):509-15. PubMed ID: 22204857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
    Nakamura H;
    Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
    Morimoto S; Koh E; Fukuo K; Higaki J; Ikegami H; Miki T; Hata T; Ogihara T
    Clin Ther; 1994; 16(5):793-803. PubMed ID: 7859238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Hyogo Pravastatin Study Group.
    Kazumi T; Yoshino G; Ishida Y; Iwatani I; Morita S; Tateiwa M; Kasuga M
    Diabetes Res Clin Pract; 1995 Jan; 27(1):61-8. PubMed ID: 7781495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Daida H; Takayama T; Hiro T; Yamagishi M; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Diabetol; 2012 Jul; 11():87. PubMed ID: 22831708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia].
    Hori E; Kikuchi C; Imaeda K; Okayama N; Suzuki T; Matsunaga T
    Yakugaku Zasshi; 2019 May; 139(5):807-815. PubMed ID: 30773524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.